These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27458154)

  • 1. Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2.
    Goldberg AA; Joung KB; Mansuri A; Kang Y; Echavarria R; Nikolajev L; Sun Y; Yu JJ; Laporte SA; Schwertani A; Kristof AS
    Oncotarget; 2016 Sep; 7(38):61152-61165. PubMed ID: 27458154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.
    Goncharova EA; Goncharov DA; Chisolm A; Spaits MS; Lim PN; Cesarone G; Khavin I; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
    Mol Pharmacol; 2008 Mar; 73(3):778-88. PubMed ID: 18094073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
    Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
    PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
    Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
    J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progesterone and estradiol synergistically promote the lung metastasis of tuberin-deficient cells in a preclinical model of lymphangioleiomyomatosis.
    Sun Y; Zhang E; Lao T; Pereira AM; Li C; Xiong L; Morrison T; Haley KJ; Zhou X; Yu JJ
    Horm Cancer; 2014 Oct; 5(5):284-98. PubMed ID: 25069840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pivotal role of augmented αB-crystallin in tumor development induced by deficient TSC1/2 complex.
    Wang F; Chen X; Li C; Sun Q; Chen Y; Wang Y; Peng H; Liu Z; Chen R; Liu K; Yan H; Ye BH; Kwiatkowski DJ; Zhang H
    Oncogene; 2014 Aug; 33(34):4352-8. PubMed ID: 24077282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis.
    Pacheco-Rodriguez G; Steagall WK; Crooks DM; Stevens LA; Hashimoto H; Li S; Wang JA; Darling TN; Moss J
    Cancer Res; 2007 Nov; 67(21):10573-81. PubMed ID: 17975002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model.
    Prizant H; Taya M; Lerman I; Light A; Sen A; Mitra S; Foster TH; Hammes SR
    Endocr Relat Cancer; 2016 Apr; 23(4):265-80. PubMed ID: 26880751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.
    Makovski V; Haklai R; Kloog Y
    Int J Cancer; 2012 Mar; 130(6):1420-9. PubMed ID: 21500191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.
    Sun Y; Gallacchi D; Zhang EY; Reynolds SB; Robinson L; Malinowska IA; Chiou TT; Pereira AM; Li C; Kwiatkowski DJ; Lee PS; Yu JJ
    Am J Respir Cell Mol Biol; 2014 Dec; 51(6):738-49. PubMed ID: 24874429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Faslodex inhibits estradiol-induced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis.
    Li C; Zhou X; Sun Y; Zhang E; Mancini JD; Parkhitko A; Morrison TA; Silverman EK; Henske EP; Yu JJ
    Am J Respir Cell Mol Biol; 2013 Jul; 49(1):135-42. PubMed ID: 23526212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TSC2 epigenetic defect in primary LAM cells. Evidence of an anchorage-independent survival.
    Lesma E; Ancona S; Sirchia SM; Orpianesi E; Grande V; Colapietro P; Chiaramonte E; Di Giulio AM; Gorio A
    J Cell Mol Med; 2014 May; 18(5):766-79. PubMed ID: 24606538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TSC2 modulates cell adhesion and migration via integrin-α1β1.
    Moir LM; Black JL; Krymskaya VP
    Am J Physiol Lung Cell Mol Physiol; 2012 Oct; 303(8):L703-10. PubMed ID: 22923640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Pluripotent Stem Cell-Derived
    Julian LM; Delaney SP; Wang Y; Goldberg AA; Doré C; Yockell-Lelièvre J; Tam RY; Giannikou K; McMurray F; Shoichet MS; Harper ME; Henske EP; Kwiatkowski DJ; Darling TN; Moss J; Kristof AS; Stanford WL
    Cancer Res; 2017 Oct; 77(20):5491-5502. PubMed ID: 28830860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis.
    Atochina-Vasserman EN; Abramova E; James ML; Rue R; Liu AY; Ersumo NT; Guo CJ; Gow AJ; Krymskaya VP
    Am J Physiol Lung Cell Mol Physiol; 2015 Dec; 309(12):L1447-54. PubMed ID: 26432869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.
    Kristof AS; You Z; Han YS; Giaid A
    Peptides; 2010 Aug; 31(8):1511-6. PubMed ID: 20433884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxycycline reduces the migration of tuberous sclerosis complex-2 null cells - effects on RhoA-GTPase and focal adhesion kinase.
    Ng HY; Oliver BG; Burgess JK; Krymskaya VP; Black JL; Moir LM
    J Cell Mol Med; 2015 Nov; 19(11):2633-46. PubMed ID: 26282580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet-derived growth factor-induced p42/44 mitogen-activated protein kinase activation and cellular growth is mediated by reactive oxygen species in the absence of TSC2/tuberin.
    Finlay GA; Thannickal VJ; Fanburg BL; Kwiatkowski DJ
    Cancer Res; 2005 Dec; 65(23):10881-90. PubMed ID: 16322235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis.
    Goncharova EA; Goncharov DA; Lim PN; Noonan D; Krymskaya VP
    Am J Respir Cell Mol Biol; 2006 Apr; 34(4):473-80. PubMed ID: 16388022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-EGFR antibody efficiently and specifically inhibits human TSC2-/- smooth muscle cell proliferation. Possible treatment options for TSC and LAM.
    Lesma E; Grande V; Ancona S; Carelli S; Di Giulio AM; Gorio A
    PLoS One; 2008; 3(10):e3558. PubMed ID: 18958173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.